SPPI op idag?
-
Spectrum Pharmaceuticals Announces the USPTO Has Granted Five-Year Extension for FOLOTYN(R) Patent
FOLOTYN
(pralatrexate injection) is the first therapeutic to have been approved for peripheral T-cell lymphoma (PTCL), in September 2009
FOLOTYN net sales were approximately $50 million in 2011
Spectrum acquired FOLOTYN through acquisition of Allos Therapeutics on September 5, 2012
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind